ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

NPS Pharma to Receive $25 Million from Amgen for Royalty Rights for Sensipar

By Victoria Stilwell NPS Pharmaceuticals Inc. (NPSP) will receive a one-time $25 million payment this month in exchange for its rights to receive royalties earned after 2018 for sales of its Sensipar drug under an amended license agreement with Amgen Inc. (AMGN). Sensipar, marketed as Mimpara in Europe, treats secondary hyperparathyroidism in chronic kidney disease patients on dialysis. In 1996 NPS licensed world-wide rights to Amgen to develop and commercialize the drug, and the drug received FDA approval in March 2004. NPS said funds from the agreement are expected to support the launches of both Gattex, a treatment for short bowel syndrome, and Natpara, which is intended to be used for adult hypoparathyroidism, in addition to aiding its transition into a self-sustaining commercial-stage business. The deal is expected to accelerate cash flow with at least $75 million of incremental cash expected through 2013. The amendment also extends the royalty-advance-repayment period, limiting the offset of the royalty advance that the biopharmaceutical company received from Amgen in August 2011 to $8 million a quarter. After repayment of the advance and a 9% anum discount factor on the balance of $92 million, Amgen will resume paying NPS all royalties earned through 2018. "This innovative transaction underscores our commitment to accessing capital at the lowest possible cost and in a manner that is in the best interests of our shareholders," said Luke M. Beshar, NPS's chief financial officer. Shares of NPS were inactive in premarket trade at $8.61, while shares of Amgen slipped 0.2% to $72.75. NPS is up 31% so far this year, while Amgen is up 14%. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/24/201516:54:55Statement of Changes in Beneficial Ownership (4)
04/24/201510:02:02Illumina's Earnings Set Positive Tone for Biotech
04/23/201517:31:15Confidential Treatment Order (ct Order)
04/23/201517:06:07Statement of Changes in Beneficial Ownership (4)
04/23/201517:02:33Nasdaq Composite Closes at Record High
04/23/201515:47:20Nasdaq Composite Rises Above March 2000 Record Close
04/23/201514:44:46AbbVie Profit Rises on Broad Sales Growth -- Update
04/23/201513:29:06Amgen, Inc. Earnings: 4 Things You Probably Overlooked
04/23/201512:03:02Is Amgen Inc.'s Dividend Sustainable?
04/23/201505:10:21Barclays Reiterates "Equal Weight" Rating for Amgen (AMGN)
04/22/201517:04:58Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201517:00:39Additional Proxy Soliciting Materials (definitive) (defa14a)
04/22/201510:49:40Amgen Price Target Raised to $195.00 (AMGN)
04/22/201510:12:19Nomura Cuts Amgen Price Target to $191.00 (AMGN)
04/22/201504:35:02Amgen PT Raised to $187.00 at Leerink Swann (AMGN)
04/22/201503:41:08RBC Capital Raises Amgen Price Target to $185.00 (AMGN)
04/21/201517:14:12Amgen Reports Higher Earnings, Outlook -- Update
04/21/201516:50:10Amgen Posts 51% Rise in Profit, Boosts Outlook
04/21/201516:35:18Amgen Posts 51% Rise in Profit, Boosts 2015 Outlook

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad